IONS
Price
$69.15
Change
+$0.75 (+1.10%)
Updated
Oct 3 closing price
Capitalization
11.02B
26 days until earnings call
MNKD
Price
$5.76
Change
+$0.27 (+4.92%)
Updated
Oct 3 closing price
Capitalization
1.77B
38 days until earnings call
Interact to see
Advertisement

IONS vs MNKD

Header iconIONS vs MNKD Comparison
Open Charts IONS vs MNKDBanner chart's image
Ionis Pharmaceuticals
Price$69.15
Change+$0.75 (+1.10%)
Volume$2.58M
Capitalization11.02B
MannKind
Price$5.76
Change+$0.27 (+4.92%)
Volume$5.13M
Capitalization1.77B
IONS vs MNKD Comparison Chart in %
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IONS vs. MNKD commentary
Oct 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IONS is a StrongBuy and MNKD is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 05, 2025
Stock price -- (IONS: $69.15 vs. MNKD: $5.76)
Brand notoriety: IONS and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IONS: 95% vs. MNKD: 112%
Market capitalization -- IONS: $11.02B vs. MNKD: $1.77B
IONS [@Biotechnology] is valued at $11.02B. MNKD’s [@Biotechnology] market capitalization is $1.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $103.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IONS’s FA Score shows that 0 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s).

  • IONS’s FA Score: 0 green, 5 red.
  • MNKD’s FA Score: 0 green, 5 red.
According to our system of comparison, MNKD is a better buy in the long-term than IONS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IONS’s TA Score shows that 3 TA indicator(s) are bullish while MNKD’s TA Score has 4 bullish TA indicator(s).

  • IONS’s TA Score: 3 bullish, 5 bearish.
  • MNKD’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, MNKD is a better buy in the short-term than IONS.

Price Growth

IONS (@Biotechnology) experienced а +7.90% price change this week, while MNKD (@Biotechnology) price change was +4.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.93%. For the same industry, the average monthly price growth was +13.10%, and the average quarterly price growth was +80.18%.

Reported Earning Dates

IONS is expected to report earnings on Oct 30, 2025.

MNKD is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+4.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IONS($11B) has a higher market cap than MNKD($1.77B). IONS YTD gains are higher at: 97.797 vs. MNKD (-10.420). MNKD has higher annual earnings (EBITDA): 79.1M vs. IONS (-170.69M). IONS has more cash in the bank: 2.29B vs. MNKD (179M). MNKD has less debt than IONS: MNKD (46.8M) vs IONS (1.42B). IONS has higher revenues than MNKD: IONS (944M) vs MNKD (302M).
IONSMNKDIONS / MNKD
Capitalization11B1.77B623%
EBITDA-170.69M79.1M-216%
Gain YTD97.797-10.420-939%
P/E RatioN/A49.91-
Revenue944M302M313%
Total Cash2.29B179M1,279%
Total Debt1.42B46.8M3,034%
FUNDAMENTALS RATINGS
IONS vs MNKD: Fundamental Ratings
IONS
MNKD
OUTLOOK RATING
1..100
1613
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
6944
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3747
P/E GROWTH RATING
1..100
6398
SEASONALITY SCORE
1..100
2690

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (56) in the Biotechnology industry is somewhat better than the same rating for IONS (95). This means that MNKD’s stock grew somewhat faster than IONS’s over the last 12 months.

MNKD's Profit vs Risk Rating (44) in the Biotechnology industry is in the same range as IONS (69). This means that MNKD’s stock grew similarly to IONS’s over the last 12 months.

IONS's SMR Rating (98) in the Biotechnology industry is in the same range as MNKD (100). This means that IONS’s stock grew similarly to MNKD’s over the last 12 months.

IONS's Price Growth Rating (37) in the Biotechnology industry is in the same range as MNKD (47). This means that IONS’s stock grew similarly to MNKD’s over the last 12 months.

IONS's P/E Growth Rating (63) in the Biotechnology industry is somewhat better than the same rating for MNKD (98). This means that IONS’s stock grew somewhat faster than MNKD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IONSMNKD
RSI
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 20 days ago
67%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGLJX16.570.09
+0.55%
MFS Global Real Estate R1
BIRDX8.660.04
+0.46%
iShares Developed Real Estate Idx Instl
GQEFX36.53N/A
N/A
GMO Quality IV
CIMDX16.79N/A
N/A
Clarkston Founders Institutional
MDODX12.00N/A
N/A
Morgan Stanley Developing Opportunity R6